Literature DB >> 21516569

Group-sequential methods for adaptive seamless phase II/III clinical trials.

Nigel Stallard1.   

Abstract

The last 10 years have seen considerable interest in clinical trial designs that allow the seamless combination of Phases II and III in a single clinical trial. Such designs bring together the selection of the most promising of a number of treatments, as usually performed in a Phase II clinical trial, with the rigorous analysis and control of type I error rates required for a Phase III clinical trial. Statistically, the challenge is that of allowing for multiple comparisons arising both from repeated analyses of the accumulating data and from selection of a treatment on the basis of data that will be included in the final analysis. This challenge can be met in a number of different ways. This paper reviews methods based on the group-sequential methodology for monitoring of sequential clinical trials. The main focus of the paper will be a description of the methodology, including the setting in which short-term data are used for decision making at an early interim analysis.

Mesh:

Year:  2011        PMID: 21516569     DOI: 10.1080/10543406.2011.551335

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  3 in total

1.  Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.

Authors:  Peter K Kimani; Susan Todd; Lindsay A Renfro; Ekkehard Glimm; Josephine N Khan; John A Kairalla; Nigel Stallard
Journal:  Stat Med       Date:  2020-05-03       Impact factor: 2.373

2.  Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

Authors:  Mary W Redman; Bryan H Goldman; Michael LeBlanc; Anne Schott; Laurence H Baker
Journal:  Clin Cancer Res       Date:  2013-05-15       Impact factor: 12.531

3.  Sensitivity of adaptive enrichment trial designs to accrual rates, time to outcome measurement, and prognostic variables.

Authors:  Tianchen Qian; Elizabeth Colantuoni; Aaron Fisher; Michael Rosenblum
Journal:  Contemp Clin Trials Commun       Date:  2017-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.